Showing 6941-6950 of 9139 results for "".
- James R. Headley Joins ELEVAI LABS as Strategic Advisorhttps://practicaldermatology.com/news/james-r-headley-joins-elevai-labs-as-strategic-advisor-a-strategic-advisor/2461450/Cosmetic industry veteran James R. Headley is joining
- CeraVe Establishes Fund at Howard University to Address Lack of Diversity in Skincare Clinical Researchhttps://practicaldermatology.com/news/cerave-establishes-fund-at-howard-university-to-address-lack-of-diversity-in-skincare-clinical-research/2461435/To help close the existing racial inequity gap in dermatological research, CeraVe is establishing a fund at Howard University to help its faculty further their expertise and build the infrastructure needed to conduct clinical trials with a focus on skin of color. Located in Washing
- NEA's Eczemawise Wins Two Top Prizes from eHealthcare Leadership Awardshttps://practicaldermatology.com/news/neas-eczemawise-wins-two-top-prizes-from-ehealthcare-leadership-awards/2461424/The
- U.S FDA Clears EndyMed’s Hair Removal Devicehttps://practicaldermatology.com/news/fda-clears-endymeds-hair-removal-device/2461393/The US Food and Drug Administration has cleared Endymed Ltd’s Pure Laser hair removal device for the marketing and sales. The Pure Laser was developed in the Company's labs by its subsidiary Endymed Medical Ltd. The Company intends to commence marketing in the US th
- Hugel Resubmits Botulax BLA to FDAhttps://practicaldermatology.com/news/hugel-resubmits-botulax-bla-to-fda-1/2461380/Hugel resubmitted the BLA for its botulinum toxin called Botulax for smoothing glabellar lines to the U.S. FDA. Hugel had received a Complete Response Letter (CRL) from the U.S. FDA last March after submitting the BLA for Botulax (50 and 100 units) to advance into the U.S. market i
- Almirall, Simcere Enter Into Licensing Agreement for IL-2-mu-Fchttps://practicaldermatology.com/news/almirall-simcere-enter-into-licensing-agreement-for-il-2-mu-fc/2461365/
- FDA Clears CellFX System for the Treatment of SHhttps://practicaldermatology.com/news/fda-clears-cellfx-system-for-the-treatment-of-sh/2461358/The U.S. Food and Drug Administration (FDA) granted Pulse Bioscience’s CellFX System (FDA) 510(k)marketing clearance for the treatment of sebaceous hyperplasia in patients with Fitzpatrick skin types I-II. This specific indication clearance enhances the CellFX
- Study: DefenAge Body Cream Improves Signs of Skin Aginghttps://practicaldermatology.com/news/study-defenage-body-cream-improves-signs-of-skin-aging/2461348/
- Antoni Ribas Receives Renewal of NCI Outstanding Investigator Awardhttps://practicaldermatology.com/news/antoni-ribas-receives-renewal-of-nci-outstanding-investigator-award/2461340/
- New Partnership for Revision Skincare, RVL Pharmaceuticalshttps://practicaldermatology.com/news/new-partnership-for-revision-skincare-rvl-pharmaceuticals/2461320/With a goal to collaborate on a variety of marketing efforts within the medical aesthetics industry, Revision Skincare® and RVL Pharmaceuticals, Inc. the owner of UPNEEQ®, are partnering to address what they see as significant unmet consumer needs. Revisions